PubMed Health⌕ Search

Biomedical subjects

M S Cardoso

Publications and source records attributed to M S Cardoso.

5 recordsLinked to original sources
PubMed1999

Experiences in HCV-NAT screening prior to releasing cellular components by the German Red Cross Blood Transfusion Service of Baden-Württemberg.

In this report we present the accumulated data on nucleic acid testing (NAT) for hepatitis C virus (HCV) RNA of blood donations by the Blood Transfusion Service of Baden-Württemberg in the period between March 1997 and March 1999. An extra barcoded blood sample was collected from each donor. Samples were tested by NAT in mini-pools of maximally 96 samples. First-time and repeat donors were tested separately. RT/HCV-PCR was performed with the COBAS HCV Amplicortrade mark, versions 1.0 and 2.0 from Roche Diagnostic Systems. Many modifications have been introduced to the original protocol since the implementation of NAT screening aiming at an increase in the sensitivity and specificity of the assay. NAT positive pools containing serologically positive samples were detected. Initially, reactive pools were identified that could not be confirmed by secondary pooling and single testing procedures. So far, no serologically negative but NAT positive sample has been found.

Blood Banks↗
PubMed1998

Mini-pool screening by nucleic acid testing for hepatitis B virus, hepatitis C virus, and HIV: preliminary results.

BACKGROUND: The purpose of this study was to evaluate the feasibility of nucleic acid testing (NAT) of mini-pools as a blood donation screening test. STUDY DESIGN AND METHODS: The stepwise implementation of NAT of mini-pools began in January 1997. Since March 1997, all blood donations collected by the German Red Cross Blood Transfusion Service of Baden-Württemberg were tested for hepatitis B virus (HBV), hepatitis C virus (HCV), and HIV nucleic acids. An extra barcoded serum sample is collected from each blood donor for NAT-based screening, which is performed only on hepatitis B surface antigen-, anti-HCV-, anti-HIV-, and anti-Treponema pallidum-seronegative donations. Samples are pooled to a maximum of 96. Positive results are resolved through intersecting subpools (a chessboard design). NAT-based screening does not include a virus concentration step before nucleic acid extraction. RESULTS: By the end of October 1997, 331, 783 donations in 3,779 pools had been screened. As yet, no viremic but seronegative blood donor has been found for the three markers. CONCLUSION: It is feasible to incorporate NAT-based screening of mini-pools into the routine virus diagnostics of a large blood transfusion service. It remains to be determined whether screening blood donations by NAT will indeed increase the safety of blood supply.

Blood Donors↗
PubMed1996

HCV transmission through blood transfusion: are HCV-RNA titer in donor serum and genotype major determinants of infection outcome?

In this paper we report the results of a retrospective investigation on anti-HCV supplemental test positive blood donors from 1993 and 1994. 22 living recipients of blood/blood components from 15 donors were localized and enrolled in the study. Serum from these individuals were tested by serological assays and RT/PCR. HCV-RNA titer was determined for all positive donors. Genotyping was performed for all HCV-RNA positive individuals (donors and recipients). We observed that less than 50% of the recipients of previous donations from those positive donors did develop serological markers of HCV infection. HCV-RNA titers in donor's serum varied from 2 x 10(3) to 5 x 10(5) copies/ml but a direct correlation between viral RNA titer and the outcome of infection could not be established. Genotype investigation revealed 100% identity of genotypes within the pairs of donors/recipients. Genotype 1 b reached a prevalence of 75% within this group.

Blood Donors↗